JoshuaDavidSchiffmanMD
Pediatric Hematology & Oncology • Salt Lake City, UTCancer Genetics/Cancer Risk Assessment, Pediatric Sarcoma Oncology
CEO & Co-Founder, Peel Therapeutics, Inc.
Dr. Schiffman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2000 Circle of Hope Dr
Salt Lake City, UT 84112Phone+1 801-587-4745Fax+1 801-662-4705
Summary
- Dr. Joshua Schiffman is a pediatric hematologist/oncologist in Salt Lake City, UT and is affiliated with multiple hospitals in the area, including Primary Children's Hospital and University of Utah Health. He received his medical degree from The Warren Alpert Medical School of Brown University and has been in practice 17 years. He specializes in cancer genetics/cancer risk assessment and pediatric sarcoma oncology. Most recently, Dr. Schiffman is the CEO and Co-Founder of Peel Therapeutics, an evolution-driven biotech company.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Pediatric Hematology/Oncology, 2004 - 2007- Stanford Health Care-Sponsored Stanford UniversityResidency, Pediatrics, 2000 - 2004
The Warren Alpert Medical School of Brown UniversityClass of 2000
Certifications & Licensure
CA State Medical License 2001 - Present
UT State Medical License 2008 - 2026- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- Biomarker in Tissue Samples From Patients With Ewing Sarcoma Start of enrollment: 2011 May 01
- Neutrophil Extracellular Trap Formation in Patients Undergoing Bone Marrow Transplant Start of enrollment: 2012 Jun 01
- Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma Start of enrollment: 2012 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 14 citationsSuggested application of HER2 breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines.Cristina Fortuno, Jessica L. Mester, Tina Pesaran, Jeffrey N. Weitzel, Jill S. Dolinsky
Human Mutation. 2020-06-12 - 270 citationsPotential Mechanisms for Cancer Resistance in Elephants and Comparative Cellular Response to DNA Damage in HumansLisa M. Abegglen, Aleah F. Caulin, Ashley Chan, Kristy Lee, Rosann Robinson
JAMA. 2015-11-03 - 240 citationsClassifying the evolutionary and ecological features of neoplasmsCarlo C. Maley, Athena Aktipis, Trevor A. Graham, Andrea Sottoriva, Amy M. Boddy
Nature Reviews. Cancer. 2017-10-01
Press Mentions
- Huntsman Cancer Institute March Research HighlightsApril 5th, 2023
PEEL Therapeutics Announces Possible New Treatment for COVID-19June 29th, 2020
Elephant Protein Destroys Human Cancer Cells, Researchers SayJanuary 19th, 2017- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
